- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05046444
Solving Riddles Through Sequencing (SIRIUS)
Testing the Diagnostic Supremacy of Sequencing-only Approaches in Hematologic Malignancies: an Observational Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
- Background and Rationale Treatment of hematological diseases relies on a single cardinal prerequisite: correct classification within the broad specter of malignant diseases arising from the hematopoietic system. With the ever-expanding availability of distinct yet complementary diagnostic tools, our understanding of the landscape of hematological diseases steadily increases. As such, the current consensus classification as summarized through the WHO classification (2017) represents a compass guiding diagnostic algorithms to the correct diagnosis. Today, the gold standard of routine diagnostic process relies on five methodological pillars: cytomorphology, histology, chromosomal cytogenetics, immunophenotyping, and molecular genetic testing. This leads to a treatment enabling diagnosis in the vast majority of cases. However, approximately 10 % of cases remain unresolved from a diagnostic point of view and hence do not lead to a satisfactory diagnosis according to current WHO standards (2017). The investigators intend to solve this issue to provide illuminating diagnostic guidance for the best possible patient´s care.
- Objectives To address this problem, the investigators hypothesize that novel high throughput sequencing methods, e.g., whole genome and/or whole transcriptome sequencing are able - by virtue of painting a more delicate genetic portrait of a tumor sample - to provide a more accurate diagnosis.
To this end the investigators generated a reference collection of 5,500 samples with the full spectrum of hematological malignancies, for which the investigators performed whole-genome sequencing as well as whole-transcriptome sequencing. Moreover, gold standard diagnoses according to WHO classification with all needed techniques, all performed in MLL, clinical data and therapy response data are fully available for these cases. The main advantage of this reference collection consists of the unambiguity of each diagnosis, providing a reference framework for any further classification and diagnosis especially in difficult cases.
Therefore, SIRIUS will compare the diagnostic superiority of WGS or WTS to the combined approach with gold standard results and by matching the obtained results to the nearest "digital sibling" within our reference cohort of more than 5,500 WGS and WTS (both in 93% of cases). To this end, the investigators will use an inhouse developed matching algorithm, which is able to match genomic or transcriptomic profiles to a group of similar cases and gold standard results from timepoint of this study. Current workflows intended to generate WTS/WGS data from patient samples - all while fulfilling state of the art accreditation (ISO 15189) - require up to 5 - 7 days. This is largely comparable to classical methods but holds the promise to replace error prone and arduous iterations in the methodological work up. The objective is to test whether WTS and/or WGS based approaches can surpass classical methods regarding diagnostic precision and routine reliability. Here the investigators will test this hypothesis in a prospective real-world setting under diagnostically difficult circumstances.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Torsten Haferlach, MD
- Phone Number: +49 (0)89 99017-100
- Email: torsten.haferlach@mll.com
Study Contact Backup
- Name: Adam Wahida, MD
- Phone Number: 004917664982845
- Email: adam.wahida@tum.de
Study Locations
-
-
-
Munich, Germany
- Recruiting
- MLL Munich Leukemia Laboratory
-
Contact:
- Torsten Haferlach, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients having been investigated with a suspected hematological disorder and:
- Having unclear diagnosis after internal routine diagnosis
- Unusual clinical course
- Unusual r/r status or non-responder
- Multiple parallel hematological conditions
- Difficult/rare therapy associated/secondary neoplasms
- Current diagnostic workup is not satisfactory in terms of (1) accuracy (2) clinical behavior
- Only samples of patients min. 18 years of age will be used
- Material with a minimum of 20% tumor content in bone marrow or peripheral blood sample
- Patient´s informed consent
Exclusion Criteria:
- Sample is not fit for state-of-the-art diagnosis, fails initial quality control. For quality insurance we will exclude samples with wrong anticoagulant sent. Samples with damage due to meteorological reasons (freeze-thaw damage or elevated temperature) will be excluded.
- Samples with to scarce material jeopardizing routine gold-standard diagnosis will be excluded (tumor content < 20 %).
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Unclear diagnosis via conventional methods
The study population consists of carefully chosen patients with potential hematological malignancy, for which current diagnostic methods were not sufficient to provide clear-cut diagnosis and definitive clinical guidance.
SIRIUS will be conducted for a total number of 110 patients with inconclusive diagnosis by gold standard techniques for a total of up to nine months after the first enrollment.
|
NON-Interventional Observation only study comparing sequencing-only approaches to classical diagnostic methods
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
sequencing only versus gold standard diagnosis
Time Frame: Time Frame of Outcome: At diagnosis for each case/patient throughout the complete duration of study for approximately 1 year.
|
The primary endpoint will be assessed as follows: unclear cases will be subjected to three diagnostic algorithms:
We will compare the accuracy for approach #3 for each patient/case by comparing the sequencing results with the therapy guiding approach in domo and Current gold-standard diagnostic workup as performed routinely by the MLL. Accuracy and overlap or discordance will be measured in percentage (%) of total cohort. Time Frame of Outcome: At diagnosis for each case/patient throughout the complete duration of study for approximately 1 year. |
Time Frame of Outcome: At diagnosis for each case/patient throughout the complete duration of study for approximately 1 year.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
turnaround time
Time Frame: The time frame will be consisting of an assessment at diagnosis for next 14 days per case/patient.
|
Turnaround time until potential therapy guiding diagnosis will be measure and compared in days.
|
The time frame will be consisting of an assessment at diagnosis for next 14 days per case/patient.
|
actionable targets
Time Frame: This outcome will be measured one year after diagnosis. (1 year after diagnosis)
|
The number of potential actionable targets will be determined for each case.
We will assess this number in absolute numbers for each patient and for which a therapy has been approved but identification was missed in during classical gold standard diagnosis.
|
This outcome will be measured one year after diagnosis. (1 year after diagnosis)
|
disease stage
Time Frame: This outcome will be measured one year after diagnosis. (1 year after diagnosis)
|
We will Identify the putative disease stage based on sequencing only approaches in comparison to normal gold standard diagnosis as well as clinical history.
Results will be denoted as percentage (%) of correctly classified cases.
|
This outcome will be measured one year after diagnosis. (1 year after diagnosis)
|
Micro-cost analysis
Time Frame: The estimated timeframe for this outcome will be the timepoint of diagnosis for each patient (approximately 5 days)
|
We will measure all costs for respective assays and personnel to finally compare workflows 2 and 3 (see primary outcome 1.).
|
The estimated timeframe for this outcome will be the timepoint of diagnosis for each patient (approximately 5 days)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MLL_002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia
-
Stanford UniversityTerminatedLeukemia | Leukemia, Lymphocytic, Acute | Leukemia Acute Promyelocytic Leukemia (APL) | Leukemia Acute Lymphoid Leukemia (ALL) | Leukemia Chronic Myelogenous Leukemia (CML) | Leukemia Acute Myeloid Leukemia (AML) | Leukemia Chronic Lymphocytic Leukemia (CLL)United States
-
Massachusetts General HospitalCelgene CorporationTerminatedAcute Myelogenous Leukemia | Acute Myeloid Leukemia (AML) | Acute Myelocytic Leukemia | Acute Granulocytic Leukemia | Acute Non-Lymphocytic LeukemiaUnited States
-
Institute of Hematology & Blood Diseases HospitalBejing Institute for Stem Cell and Regenerative Medicine; Institute for Stem...RecruitingRefractory Leukemia | Relapsed Leukemia | Acute Myeloid Leukemia, ChildhoodChina
-
Betta Pharmaceuticals Co., Ltd.Not yet recruitingAcute Myeloid Leukemia LeukemiaChina
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia Without Maturation (M1) | Childhood Acute Myelomonocytic Leukemia (M4) | Childhood Acute Myeloid Leukemia/Other Myeloid MalignanciesUnited States
-
Hybrigenics CorporationUnknownAcute Myelogenous LeukemiaUnited States, France
-
Massachusetts General HospitalCompleted
-
Beijing Boren HospitalRecruitingAcute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Relapse LeukemiaChina
-
Kinex Pharmaceuticals Inc.CompletedAcute Myelogenous LeukemiaUnited States
-
National Cancer Institute (NCI)TerminatedAdult Acute Megakaryoblastic Leukemia (M7) | Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Adult Acute Monoblastic Leukemia (M5a) | Adult Acute Monocytic Leukemia (M5b) | Adult Acute Myeloblastic Leukemia With Maturation (M2) | Adult Acute Myeloblastic Leukemia Without Maturation... and other conditionsUnited States
Clinical Trials on Next Generation Sequencing
-
Asan Medical CenterRecruitingPancreatic Cancer | Chemotherapy Effect | Genetic ChangeKorea, Republic of
-
Qingyuan ZhanNot yet recruiting
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingThis Study Aims to Reveal the Effectiveness, Accuracy, and Feasibility in BileChina
-
Aarhus University HospitalRecruiting
-
Shanghai Pulmonary Hospital, Shanghai, ChinaRecruitingIdiopathic Interstitial Pneumonias | Cryptogenic Organizing PneumoniaChina
-
University Hospital, Basel, SwitzerlandFachhochschule NordwestschweizWithdrawnActive TuberculosisSwitzerland
-
Guangzhou Institute of Respiratory DiseaseCompleted
-
Second Affiliated Hospital, School of Medicine,...Completed
-
Rothman Institute OrthopaedicsUnknownStaphylococcus Aureus | Total Joint Arthroplasty | Next Generation SequencingUnited States
-
Sun Yat-sen UniversityUnknownLung Cancer | Brain Metastases | Cerebrospinal Fluid | Next-generation SequencingChina